Europe's IMI Sets Pace for Public/Private Partnerships in Pharmaceutical Development

A recent PharmaTimes article highlighted the efforts of the largest public/private partnership in the pharmaceutical industry, Europe’s Innovative Medicines Initiative (IMI).  The IMI, jointly funded for 2 billion euros by the European Commission and the industry group, the European Federation of Pharmaceutical Industries and Associations (EFPIA), seeks to address the development and delivery issues for critical new medicines that may be too large for an individual institution or company to tackle alone.

According to PharmaTimes, the IMI focuses on “unmet needs common to the pharmaceutical industry and patients – the key concepts being pre-competitive research, open innovation and patient-tailored therapies.”   Now in its third year accepting proposals, the initiative will target a number of new developments in pharmaceuticals and patient education, including the development of personalized medicine approaches for the treatment of diabetes and a variety of training programs for creating “informed patients.”

Ongoing projects like the Innovative Medicines Initiative and Italy’s Drug Development and Discovery Unit (see our previous post about the D3 here) are opening up greater opportunities for the pharmaceutical industry to pool its resources and work with the medical community for better public health.

More Posts

New White Paper on Patient Engagement

Technological and cultural forces are shifting the expectations that patients bring to their healthcare. Armed with the ever-growing availability of information (and misinformation) on the

New White Paper on Building Speakers Bureaus

The pharmaceutical industry has long used speakers bureaus and their associated meetings and events to educate healthcare providers (HCPs) about drug therapies and the diseases those drugs

Focus on Micro-Influencers

By Brian Castle, Digital Insights Lead Influencers and micro-influencers both play a key role in medical innovation and communication. Let’s discuss the difficult task of


Send Us A Message